In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final ...

GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals. The company's product portfolio includes prescription medicines and ...

Flagship Pioneering has signed yet another strategic-level deal with a big pharma group, with GSK the latest to tap into its network of biotech companies in an alliance that could be worth more ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Short Sellers. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the ...

GlaxoSmithKline (GSK) is set to apply artificial intelligence (AI) technology to improve its drug discovery efforts through a collaboration with Cloud Pharmaceuticals. Its deal with the US-based ...

As one of the fastest-growing major economies in the world, India has recorded a GDP growth of 7.6%* in FY 2023-24, owing to a strong rebound in economic activity. Rising disposable income levels ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

32 per equity share for the year. This dividend for the year ended 31 March 2024 is subject to the approval of Members at the Annual General Meeting on 28 June 2024 and will be paid on or after 1 ...

Global pharma giant GlaxoSmithKline Pharmaceuticals Ltd received an income tax refund of ₹222.23 crore for the assessment year 2022-23, following an order issued by the Income Tax Department on ...

"Given the unmet medical need and burden associated with genital herpes, innovation in this area is still needed. GSK intends to evaluate the totality of all these data and other studies to progress ...

It was one of those conversations you never forget. We were discussing – of all things – the Covid injections, and I was questioning the early ‘safe and effective’ claims put forward by the pharmaceut ...

(Alliance News) - GSK PLC on Friday announced that it has been granted breakthrough therapy designation in China for Blenrep, a treatment for relapsed or refractory multiple myeloma.